RNF31 induces paclitaxel resistance by sustaining ALYREF cytoplasmic–nuclear shuttling in human triple-negative breast cancer

Abstract

	•RNF31 facilitated ALYREF-mediated PTX resistance in TNBC.
	•RNF31 promoted ALYREF nuclear transport via IPO13 in response to PTX treatment, subsequently enhancing the export of mRNAs encoding PTX resistance-related factors, including TUBB3, STMN1, and TAU.
	•Blocking RNF31 trapped ALYREF in the cytoplasm and induced TNBC cell death upon PTX treatment.
	•Inhibiting RNF31 activity re-sensitized PTX-resistant TNBC to PTX treatment.

Keywords

ALYREF / cytoplasmic–nuclear shuttling / paclitaxel resistance / triple-negative breast cancer

References

[1] GiaquintoAN, SungH, MillerKD, et al. Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022; 72: 524-541.

[2] BianchiniG, De Angelis C, LicataL, GianniL. Treatment landscape of triple-negative breast cancer—expanded options, evolving needs. Nat Rev Clin Oncol. 2022; 19: 91-113.

[3] GeyerCE, SikovWM, HuoberJ, et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann Oncol. 2022; 33: 384-394.

[4] YuKD, YeFG, HeM, et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2020; 6: 1390-1396.

[5] LoiblS, Schneeweiss A, HuoberJ, et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol. 2022; 33: 1149-1158.

[6] SchmidP, CortesJ, DentR, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022; 386: 556-567.

[7] ZagamiP, CareyLA. Triple negative breast cancer: pitfalls and progress. NPJ Breast Cancer. 2022; 8: 95.

[8] MoscaL, IlariA, FaziF, Assaraf YG, ColottiG. Taxanes in cancer treatment: activity, chemoresistance and its overcoming. Drug Resist Updat. 2021; 54: 100742.

[9] LiuR, LiangX, GuoH, et al. STNM1 in human cancers: role, function and potential therapy sensitizer. Cell Signal. 2023; 109: 110775.

[10] GanPP, Pasquier E, KavallarisM. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res. 2007; 67: 9356-9363.

[11] LinH, ZhengL, LiS, et al. Cytotoxicity of Tanshinone IIA combined with Taxol on drug-resist breast cancer cells MCF-7 through inhibition of Tau. Phytother Res. 2018; 32: 667-671.

[12] LiaoL, ZhangYL, DengL, et al. Protein phosphatase 1 subunit PPP1R14B stabilizes STMN1 to promote progression and paclitaxel resistance in triple-negative breast cancer. Cancer Res. 2023; 83: 471-484.

[13] WickramasingheVO, Laskey RA. Control of mammalian gene expression by selective mRNA export. Nat Rev Mol Cell Biol. 2015; 16: 431-442.

[14] MarulloR, Rutherford SC, RevueltaMV, et al. XPO1 enables adaptive regulation of mRNA export required for genotoxic stress tolerance in cancer cells. Cancer Res. 2024; 84: 101-117.

[15] NewellS, van der Watt PJ, LeanerVD. Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy. IUBMB Life. 2024; 76: 4-25.

[16] BaiX, NiJ, BeretovJ, et al. THOC2 and THOC5 regulate stemness and radioresistance in triple-negative breast cancer. Adv Sci (Weinh). 2021; 8: e2102658.

[17] XuZ, LiX, LiH, et al. Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA. Oncogene. 2020; 39: 7051-7062.

[18] LiY, WangM, YangM, et al. Nicotine-induced ILF2 facilitates nuclear mRNA export of pluripotency factors to promote stemness and chemoresistance in human esophageal cancer. Cancer Res. 2021; 81: 3525-3538.

[19] NagyZ, Seneviratne JA, KanikevichM, et al. An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability. Nat Commun. 2021; 12: 1881.

[20] KlecC, Knutsen E, SchwarzenbacherD, et al. ALYREF, a novel factor involved in breast carcinogenesis, acts through transcriptional and post-transcriptional mechanisms selectively regulating the short NEAT1 isoform. Cell Mol Life Sci. 2022; 79: 391.

[21] XueC, GuX, ZhengQ, et al. ALYREF mediates RNA m(5)C modification to promote hepatocellular carcinoma progression. Signal Transduct Target Ther. 2023; 8: 130.

[22] WangJZ, ZhuW, HanJ, et al. The role of the HIF-1alpha/ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancer. Cancer Commun (Lond). 2021; 41: 560-575.

[23] MengQ, XieY, SunK, et al. ALYREF-JunD-SLC7A5 axis promotes pancreatic ductal adenocarcinoma progression through epitranscriptome-metabolism reprogramming and immune evasion. Cell Death Discov. 2024; 10: 97.

[24] ZhouZ, LuoMJ, StraesserK, Katahira J, HurtE, ReedR. The protein Aly links pre-messenger-RNA splicing to nuclear export in metazoans. Nature. 2000; 407: 401-405.

[25] OkadaM, JangSW, YeK. Akt phosphorylation and nuclear phosphoinositide association mediate mRNA export and cell proliferation activities by ALY. Proc Natl Acad Sci U S A. 2008; 105: 8649-8654.

[26] YangX, YangY, SunBF, et al. 5-methylcytosine promotes mRNA export—NSUN2 as the methyltransferase and ALYREF as an m(5)C reader. Cell Res. 2017; 27: 606-625.

[27] De MagistrisP. The great escape: mRNA export through the nuclear pore complex. Int J Mol Sci. 2021; 22: 11767.

[28] MackmullMT, KlausB, HeinzeI, et al. Landscape of nuclear transport receptor cargo specificity. Mol Syst Biol. 2017; 13: 962.

[29] ChristopheD, Christophe-Hobertus C, PichonB. Nuclear targeting of proteins: how many different signals? Cell Signal. 2000; 12: 337-341.

[30] ZenklusenD, Vinciguerra P, StrahmY, StutzF. The yeast hnRNP-Like proteins Yra1p and Yra2p participate in mRNA export through interaction with Mex67p. Mol Cell Biol. 2001; 21: 4219-4232.

[31] KashyapAK, Schieltz D, YatesJ 3rd, KelloggDR. Biochemical and genetic characterization of Yra1p in budding yeast. Yeast. 2005; 22: 43-56.

[32] KodihaM, ChuA, MatusiewiczN, StochajU. Multiple mechanisms promote the inhibition of classical nuclear import upon exposure to severe oxidative stress. Cell Death Differ. 2004; 11: 862-874.

[33] YangM, LiY, KongL, et al. Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer. J Clin Invest. 2023; 133: e164428.

[34] ChakrabortyS, Karmakar S, BasuM, KalS, GhoshMK. The E3 ubiquitin ligase CHIP drives monoubiquitylation-mediated nuclear import of the tumor suppressor PTEN. J Cell Sci. 2023; 136: jcs260950.

[35] HuangY, LiJ, DuW, et al. Nuclear translocation of the 4-pass transmembrane protein Tspan8. Cell Res. 2021; 31: 1218-1221.

[36] KirisakoT, KameiK, MurataS, et al. A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J. 2006; 25: 4877-4887.

[37] EmmerichCH, Ordureau A, StricksonS, et al. Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains. Proc Natl Acad Sci U S A. 2013; 110: 15247-15252.

[38] WangP, DaiX, JiangW, Li Y, WeiW. RBR E3 ubiquitin ligases in tumorigenesis. Semin Cancer Biol. 2020; 67: 131-144.

[39] ZhangJ, TuH, ZhengZ, Zhao X, LinX. RNF31 promotes tumorigenesis via inhibiting RIPK1 kinase-dependent apoptosis. Oncogene. 2023; 42: 1585-1596.

[40] ZhangZ, KongX, LigtenbergMA, et al. RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells. Cell Rep Med. 2022; 3: 100655.

[41] YangH, XueM, SuP, et al. RNF31 represses cell progression and immune evasion via YAP/PD-L1 suppression in triple negative breast cancer. J Exp Clin Cancer Res. 2022; 41: 364.

[42] SachsN, de Ligt J, KopperO, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 2018; 172: 373-386 e310.

[43] Pacheco-FiallosB, Vorlander MK, Riabov-BassatD, et al. mRNA recognition and packaging by the human transcription-export complex. Nature. 2023; 616: 828-835.

[44] LitiereS, IsaacG, De VriesEGE, et al. RECIST 1.1 for response evaluation apply not only to chemotherapy-treated patients but also to targeted cancer agents: a pooled database analysis. J Clin Oncol. 2019; 37: 1102-1110.

[45] ZuoY, FengQ, JinL, et al. Regulation of the linear ubiquitination of STAT1 controls antiviral interferon signaling. Nat Commun. 2020; 11: 1146.

[46] IzaurraldeE, KutayU, von KobbeC, Mattaj IW, GorlichD. The asymmetric distribution of the constituents of the Ran system is essential for transport into and out of the nucleus. EMBO J. 1997; 16: 6535-6547.

[47] AyanlajaAA, JiG, WangJ, et al. Doublecortin undergo nucleocytoplasmic transport via the RanGTPase signaling to promote glioma progression. Cell Commun Signal. 2020; 18: 24.

[48] YasudaY, Miyamoto Y, SaiwakiT, YonedaY. Mechanism of the stress-induced collapse of the Ran distribution. Exp Cell Res. 2006; 312: 512-520.

[49] StochajU, Rassadi R, ChiuJ. Stress-mediated inhibition of the classical nuclear protein import pathway and nuclear accumulation of the small GTPase Gsp1p. FASEB J. 2000; 14: 2130-2132.

[50] GajewskaKA, JansDA, WagstaffKM. The nuclear transporter importin 13 can regulate stress-induced cell death through the clusterin/KU70 axis. Cells. 2023; 12: 279.

[51] GajewskaKA, Lescesen H, RamialisonM, WagstaffKM, JansDA. Nuclear transporter Importin-13 plays a key role in the oxidative stress transcriptional response. Nat Commun. 2021; 12: 5904.

[52] YangY, GuoL, ChenL, Gong B, JiaD, SunQ. Nuclear transport proteins: structure, function, and disease relevance. Signal Transduct Target Ther. 2023; 8: 425.

[53] BischoffFR, Krebber H, SmirnovaE, DongW, Ponstingl H. Co-activation of RanGTPase and inhibition of GTP dissociation by Ran-GTP binding protein RanBP1. EMBO J. 1995; 14: 705-715.

[54] DattiloV, D’Antona L, TalaricoC, et al. SGK1 affects RAN/RANBP1/RANGAP1 via SP1 to play a critical role in pre-miRNA nuclear export: a new route of epigenomic regulation. Sci Rep. 2017; 7: 45361.

[55] MasudaS, DasR, ChengH, Hurt E, DormanN, ReedR. Recruitment of the human TREX complex to mRNA during splicing. Genes Dev. 2005; 19: 1512-1517.

[56] FribourgS, BraunIC, IzaurraldeE, Conti E. Structural basis for the recognition of a nucleoporin FG repeat by the NTF2-like domain of the TAP/p15 mRNA nuclear export factor. Mol Cell. 2001; 8: 645-656.

[57] FanJ, KuaiB, WuG, et al. Exosome cofactor hMTR4 competes with export adaptor ALYREF to ensure balanced nuclear RNA pools for degradation and export. EMBO J. 2017; 36: 2870-2886.

[58] LuX, AnL, FanG, et al. EGFR signaling promotes nuclear translocation of plasma membrane protein TSPAN8 to enhance tumor progression via STAT3-mediated transcription. Cell Res. 2022; 32: 359-374.

[59] ShiD, WuX, JianY, et al. USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer. Nat Commun. 2022; 13: 5644.

[60] DurairajG, GargP, BhaumikSR. Nuclear export of mRNA and its regulation by ubiquitylation. RNA Biol. 2009; 6: 531-535.

[61] MacKayC, Carroll E, IbrahimAFM, et al. E3 ubiquitin ligase HOIP attenuates apoptotic cell death induced by cisplatin. Cancer Res. 2014; 74: 2246-2257.

[62] ZhuJ, ZhaoC, Kharman-BizA, et al. The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor alpha and modulates estrogen-stimulated breast cancer cell proliferation. Oncogene. 2014; 33: 4340-4351.

[63] SakamotoH, Egashira S, SaitoN, et al. Gliotoxin suppresses NF-kappaB activation by selectively inhibiting linear ubiquitin chain assembly complex (LUBAC). ACS Chem Biol. 2015; 10: 675-681.

[64] JimboK, Hattori A, KoideS, et al. Genetic deletion and pharmacologic inhibition of E3 ubiquitin ligase HOIP impairs the propagation of myeloid leukemia. Leukemia. 2023; 37: 122-133.

[65] JoT, Nishikori M, KogureY, et al. LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells. Blood. 2020; 136: 684-697.

[66] KatsuyaK, OikawaD, IioK, et al. Small-molecule inhibitors of linear ubiquitin chain assembly complex (LUBAC), HOIPINs, suppress NF-kappaB signaling. Biochem Biophys Res Commun. 2019; 509: 700-706.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.